Home » Topics » BioWorld Science

BioWorld Science
RSS

ImClone and Immunex crosslicense flt3/flk-2 technology

Dec. 23, 1996

First Rx for oral ulcers cleared by FDA

Dec. 23, 1996

ALRT-1550 to enter clinical trials

Dec. 23, 1996

Additional filings and positive clinical results for Zadaxin

Dec. 23, 1996

Anti-CD2 MAb enters phase II for GVHD

Dec. 23, 1996

Biomatrix-Boehringer Ingelheim Synvisc agreement

Dec. 23, 1996

Third approval for Parke-Davis HMG-CoA reductase inhibitor

Dec. 23, 1996

Biomerica and Bentley sign marketing and distribution agreement

Dec. 23, 1996

QLT signs European licensing agreement for photosensitizer

Dec. 23, 1996

NIH HIV immunoassay licensed to IGEN

Dec. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...